Overall, our findings echo those of Mitou et al., and they are in support of the concept of combining autophagy inhibitors and tyrosine kinase inhibitors in treating ALK + ALCL patients, although the current study has highlighted the importance of this therapeutic strategy in eliminating the cancer stem-like cell population. This evidence concerns the gene ALK and cancer.